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Abstract 
Background: Exposure to ammonium persulfate (AP) has been reported to be the main cause of occupational 
asthma in hairdressers. The aim of this study is to assess how long the asthmatic response to AP can be induced after 
dermal sensitization in a mouse model.
Methods: BALB/c mice received dermal applications of AP or dimethylsulfoxide (DMSO) (control) on days 1 and 8. 
They then received a single nasal instillation (challenge) of AP or saline on days 15, 22, 29, 36, 45, 60 and 90. Respira‑
tory responsiveness to methacholine was measured 24 h after the challenge using a non‑specific methacholine 
provocation test. Pulmonary inflammation was analysed in bronchoalveolar lavage (BAL), and total serum immuno‑
globulin (Ig) E, IgG1 and IgG2a were measured in serum samples. Histological analysis of lung slides was performed.
Results: Mice dermally sensitized and intranasally challenged with AP showed respiratory responsiveness to metha‑
choline as long as 45 days after initial sensitization, as well as increased percentage of neutrophils in BAL compared 
with the control group. At day 60, dermally sensitized mice still presented bronchial hyperresponsiveness, while the 
percentage of neutrophils returned to baseline levels similar to those of controls. Total serum IgE increased signifi‑
cantly on day 22 after dermal sensitization. Total serum IgG1 and IgG2a increased from 45 days after dermal sensitiza‑
tion and remained high at 90 days.
Conclusions: Both respiratory responsiveness to methacholine and airway inflammation responses decrease with 
increasing time between sensitization and challenge. Respiratory responsiveness to methacholine tends to persist 
longer than inflammation.
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Background
Persulfate salts are highly reactive low molecular weight 
(LMW) chemical compounds which are present in 
considerable proportions (10–20  %) in the bleaching 
powders used by hairdressers during hair-bleaching pro-
cedures [1]. Exposure to these salts has been identified 
as the main cause of immunological sensitization and 
subsequent allergic diseases such as contact dermatitis 
and bronchial asthma, and it has been associated with 
a high risk of occupational asthma (OA) in hairdressers 
[2–4].
Nevertheless, the mechanisms by which persulfate salts 
induce sensitization and OA are not well established [5]. 
An immunologic mechanism has been postulated; vari-
ous authors have suggested an IgE-driven mechanism, 
based on skin prick test positivity to persulfate salts and 
the finding of high levels of total serum IgE in hairdress-
ers with OA [4, 6]. However, other data seem to sug-
gest that persulfate salts act through an immunological 
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mechanism without driving an IgE response [7]. There-
fore, studies of OA using suitable animal models may be 
able to shed light on the processes involved in the onset 
and persistence of bronchial hyperresponsiveness and 
airway inflammation and remodeling.
In a previous study using local lymph node assays [8], 
our research group identified ammonium persulfate (AP) 
as a moderate dermal sensitizer. In later work we devel-
oped and validated a mouse model of chemical-induced 
asthma using AP. In this model, mice were dermally sen-
sitized with AP and then underwent a single airway chal-
lenge with AP, which triggered the responses typical of 
human OA [8, 9].
It has been reported that asthma symptoms and non-
specific airway hyperresponsiveness persist even after 
cessation of exposure. The reason for this is not clear. In 
the present study, we examined how long the asthmatic 
response to AP persists after dermal sensitization. The aim 
of the study was to compare the airway responses, lung 
inflammation, and immune responses induced by a single 
intranasal AP challenge administered at variable intervals 
(between 1 and 90 days) after dermal sensitization to AP.
Methods
Mouse model of chemical‑induced asthma
On days 1 and 8, male BALB/c mice (~20 g, 6 weeks old; 
Harlan, The Netherlands) received dermal applications 
of 5 % ammonium persulfate (AP, [(NH4)2S2O8], Sigma-
Aldrich, Steinheim, Germany) or vehicle (dimethylsulfox-
ide (DMSO), Sigma-Aldrich, Steinheim, Germany) on the 
dorsum of both ears (20 µl). On days 15, 22, 29, 36, 45, 60 
and 90, under light anesthesia with isoflurane (Forane®, 
Abbott Laboratories, Madrid, Spain), mice received an 
intranasal instillation (40 µl) of 1 % AP or vehicle (saline, 
0.9  %NaCl). The experimental groups were DMSO/SAL 
and AP/AP: the first abbreviation identifies the agent 
used for dermal applications on days 1 and 8 (sensitiza-
tion) and the second identifies the agent administered via 
intranasal instillation on days 15, 22, 29, 36, 45, 60 and 90 
(challenge). Each group of mice (vehicle or AP) consisted 
of five to eight animals at each time point. The experi-
ments were repeated twice per group.
Respiratory responsiveness to methacholine
One day after intranasal challenge, reactivity in response 
to methacholine was measured using a forced oscillation 
technique (FlexiVent, SCIREQ, Montreal, Canada). As 
previously described, mice were anesthetized with pento-
barbital (70  mg/kg body weight) (Nembutal ®, Abbot 
Laboratories) and airway resistance (R) was measured 
using a “snapshot” protocol. For each mouse, R was plot-
ted against methacholine concentration (0–20  mg/ml) 
and the area under the curve (AUC) was calculated [10].
Total serum immunoglobulins
After functional airway measurements, mice were deeply 
anesthetized by an intraperitoneal injection of pentobar-
bital (90 mg/kg body weight). Blood was taken from the 
retro-orbital plexus and centrifuged (14,000g, 10  min) 
and serum samples were stored at −80  °C for further 
analyses. The mouse ELISA kits (Bethyl Laboratories 
Inc., Montgomery, USA) were used to measure total 
serum immunoglobulin (Ig)-E, IgG1 and IgG2a (diluted 
samples 1/5, 1/12,500 and 1/5000 respectively). Measure-
ments were performed according to the manufacturer’s 
instructions, using biotinylated anti-mouse IgE, IgG1 or 
IgG2a detection antibodies and horseradish peroxidase 
conjugate.
Pulmonary inflammation in bronchoalveolar lavage
Once blood samples were collected, bronchoalveolar 
lavage (BAL) was performed in situ. The lungs were lav-
aged three times with 0.7 ml sterile saline (0.9 % NaCl), 
and the fluid recovered was pooled. Cells were counted 
using a Bürker hemocytometer (total cells) and the bron-
choalveolar lavage (BAL) fluid was centrifuged (1000g, 
10 min). For differential cell counts, 250 µl of the resus-
pended cells (100,000 cells/ml) were spun (300g, 6 min) 
(Cytospin 3, Shandon, Thermo Scientific, Cheshire, 
United Kingdom) onto microscope slides, air-dried and 
stained [May-Grünwald, 5 min (QCA; Tarragona, Spain) 
and Giemsa, 15 min (Merck, Darmstadt, Germany)]. For 
each sample, the numbers of macrophages, eosinophils, 
neutrophils and lymphocytes were counted in 500 cells.
Lung pathology
After BAL, lungs were instilled with formaldehyde 3.7–
4.0  % until all lobes were deemed to be fully inflated by 
visual inspection. Instillation was always performed by the 
same person and in homogeneous conditions. Evaluation 
of lung injury on slides stained by haematoxylin and eosin 
(H&E) and Masson’s trichrome was performed by an expe-
rienced pathologist in a blinded manner. A semi-quanti-
tative scoring system was used to grade the severity and 
extent of inflammation, as well as bronchiolar epithelium 
hyperplasia on H&E stained sections. The thickness of the 
infiltrate in the interalveolar septa and hyperplasia was 
graded as follows: 0 (normal) = absence of inflammatory 
cells; 1 (mild) = 1–2 layers of inflammatory cells; 2 (mod-
erate) = 3–5 layers; 3 (severe) = more than 5 layers [11].
Data analysis
All data are presented as mean ± standard deviation (SD) 
and were analysed using the non-parametric Kruskal–
Wallis test and Mann–Whitney U-test (Graphpad Prism 
4.01, Graphpad Software Inc, San Diego, USA). A level of 
p < 0.05 (two-tailed) was considered significant.
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Results
Respiratory responsiveness to methacholine
The non-specific total respiratory resistance to methacho-
line increased 24 h after the intranasal instillation with AP 
in the groups of mice which received dermal treatment 
with AP and were also intranasally challenged with AP (the 
AP/AP group) at time points 15, 22, 29, 36, 45 and 60 days 
(Fig. 1a, b), compared to the control groups which received 
dermal treatment with DMSO and were intranasally chal-
lenged with saline (the DMSO/SAL group), At the last time 
point, after receiving a single challenge with AP on day 90, 
no changes in non-specific total respiratory resistance to 
methacholine were found in the AP/AP mice (Fig. 1a, b).
Total serum immunoglobulins
Total serum IgE levels showed a trend towards an 
increase on day 15 (p = 0.083), and increased significantly 
on day 22 in the AP/AP group compared with the control 
mice (Fig. 2a). Total serum IgG1 and IgG2a levels in AP-
treated mice started to increase later than total serum 
IgE. In the case of IgG2a, the increase became signifi-
cant 60 days after the first dermal sensitization, and was 
maintained after 90 days; in the case of IgG1 there was a 
trend towards an increase, although it did not reach sig-
nificance (p = 0.076) (Fig. 2b, c).
Pulmonary inflammation (bronchoalveolar lavage)
Figure  3 shows the BAL neutrophil count 1  day after a 
single challenge. AP-treated mice (AP/AP) showed sig-
nificantly higher percentages of BAL neutrophils at time 
points 15, 22, 29, 36 and 45  days than the DMSO/SAL 
control group (Fig.  3). There were no significant differ-
ences in the percentages of eosinophils and lymphocytes 
in BAL samples between the groups (data not shown).
a
b
Fig. 1 Respiratory responsiveness to methacholine expressed as area under the curve (AUC) of the resistance (R) 24 h after intranasal instillation of 
AP or vehicle (saline). Experimental groups were DMSO/SAL and AP/AP and were consisted in 5–8 mice per group. First abbreviation refers to der‑
mal sensitization (day 1 and 8), and the second to the agents administered via intranasal instillation (day 15, 22, 29, 36, 45, 60, 90). a Mean ± SD of 
AUC of R against methacholine concentrations (0–20 mg/ml). b Mean individual values of AUC at 15, 36, 60 and 90 days after challenge. *p < 0.05, 
**p < 0.01 compared with DMSO/SAL. AHR airway hyperresponsiveness; AP ammonium persulfate; AUC area under the curve; DMSO dimethylsulfox‑
ide; SAL saline




Fig. 2 Total serum immunoglobulin (Ig)‑E, IgG1 and IgG2a. Blood was collected 24 h after intranasal instillation of AP or vehicle (saline). Total serum 
IgE, IgG1 and IgG2a were measured using a standard ELISA. Experimental groups are the same as in Fig. 1 and were consisted in 4–6 mice per 
group. a Mean ± SD of total serum IgE. b Mean ± SD of total serum IgG1. c Mean ± SD of total serum IgG2a. *p < 0.05 compared with DMSO/SAL 
control group. AP ammonium persulfate; DMSO dimethylsulfoxide; SAL saline
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Airway histopathology
A blinded histopathological examination of lung tis-
sue sections from the AP-treated mice assessed as long 
as 60  days after sensitization revealed an increase in 
inflammatory cell infiltration (grade 1–2, mild to moder-
ate) and the presence of alveolar macrophages (grade 1, 
mild) (Fig. 4a, b) compared with control groups (Fig. 4d, 
e). At 90 days, the stained sections of AP/AP mice pre-
sented reductions in inflammatory cell infiltration (grade 
0–1, normal to mild) (Fig.  4c, f ). Selectively, at 15  days 
some moderate peribronchiolar epithelium hyperplasia 
was observed in the AP/AP group (grade 2, moderate) 
(Fig.  4a) compared with controls (Fig.  4d). In this acute 
single challenge model, no collagen deposition was found 
in the lung sections stained with Masson’s trichrome 
(data not shown).
Discussion
We investigated the time course of immunologic and 
respiratory responses after dermal sensitization in a vali-
dated mouse model of OA due to persulfate salts [9]. We 
were able to induce both respiratory responsiveness to 
methacholine and pulmonary inflammation in AP-sen-
sitized mice with a single intranasal challenge with AP 
up to 40 days after initial AP sensitization. Even 60 days 
after initial AP sensitization, a single challenge could 
still induce respiratory responsiveness (without neutro-
philic inflammation), while 90  days afterwards, a single 
challenge with AP no longer induced these asthma-like 
symptoms. In terms of the immune response, there was 
evidence of systemic sensitization (with an increase in 
IgE) at early stages, while high IgG levels appeared later.
Exposure to persulfate salts is associated with a high 
risk of developing OA, although the mechanisms by 
which these substances induce sensitization and OA are 
not well understood [2, 4]. It has been suggested that 
persulfate-induced OA is mediated by an immunologi-
cal mechanism [2, 4, 12]. Positive skin prick tests to per-
sulfates have been reported, suggesting an IgE-mediated 
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Fig. 3 Percentage of neutrophils in BAL obtained 24 h after intranasal 
instillation of AP or vehicle (saline). Experimental groups are the same 
as in Fig. 1 and were consisted in 5–8 mice per group. Mean ± SD of 
percentage of neutrophils in BAL. *p < 0.05 compared with DMSO/
SAL control group. No significant differences were found in the other 
groups studied at different time points. AP ammonium persulfate, BAL 
bronchoalveolar lavage, DMSO dimethylsulfoxide, SAL saline





Fig. 4 Lung histopathology. Representative images of haematoxylin and eosin stained histological lung sections. Experimental groups in this figure 
are represented with sections from DMSO/SAL, and AP/AP groups assessed 15 (a and d), 45 (b and e) and 90 (c and f) days after AP sensitization. AP 
ammonium persulfate, DMSO dimethylsulfoxide, SAL saline
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has been described in studies with human patients and 
with mouse models [4, 9]. In this connection, in a mouse 
model of chemical-induced asthma previously developed 
by our group using AP [9], we showed that AP, after two 
dermal applications and only one airway challenge, can 
induce features of human occupational asthma in mice, 
including respiratory responsiveness to methacholine, 
neutrophil inflammation in BAL, T- and B cell prolifer-
ation and a Th2 cytokine profile in the auricular lymph 
nodes (the site of sensitization), and also increased total 
serum IgE levels.
Recent animal and human data collectively support a 
central role for skin barrier function and skin exposure 
in the development of Th2-like sensitization and the sub-
sequent development of asthma. Mouse models have 
also shown that chemicals can induce mixed Th1/Th2 
responses [15, 16]. The skin may play a role both as an 
important route of exposure and as an immunological 
organ that can contribute to pulmonary immune diseases 
[17]. The epidermis contains keratinocytes and Langer-
hans cells, a major dendritic cell in the skin which can 
acquire antigen, migrate to draining lymph notes, and ini-
tiate immune responses [18]. The activation of dendritic 
cells with subsequent T-lymphocyte transformation in 
the lymph nodes draining the skin produces activated 
effector T-lymphocytes or memory cells in the systemic 
circulation [19]. Once in the lung, effector T-cells will 
produce cytokines and chemokines or undertake cyto-
toxic functions. Repeated lung exposure to the irritant by 
inhalation doses may synergistically amplify this allergic 
inflammation and asthma. These cells are able to express 
high-affinity receptors for IgE and, upon re-exposure, 
binding of the allergen to IgE orchestrates the immune 
system to initiate a more aggressive and rapid memory 
response [20].
In this study, we found a trend towards an increase 
in total serum IgE levels already at 15  days after initial 
dermal application of AP. IgE levels remained high until 
22  days. A previous study by our group [21] described 
the course of bronchial hyperresponsiveness and immu-
nologic test results in patients with OA due to persulfate 
salts, and found that total IgE levels remained increased 
even in patients who ceased exposure. On the other 
hand, levels of total serum IgG1 tended to increase from 
day 60, when total serum IgE levels had returned to base-
line values. This is compatible with a Th2 immunologi-
cal response, despite the unexpected increases in levels 
of total serum IgG2a (characteristic of a Th1 stimulation 
in mice) from day 60. These results are consistent with 
other studies carried out by our group with the same 
animal model and other mouse models of asthma using 
LMW agents [9, 11, 20–23], which suggested a mixed 
Th2-Th1-type immune response in sensitized mice. It 
has also been proposed that an increase in IgG levels may 
have a protective effect in this animal model [24], as the 
percentage of neutrophils decreased at the same time 
point that IgG started to increase.
Nevertheless, respiratory responsiveness to methacho-
line still persisted at 45 days despite the increased levels 
of IgG. Thus, inflammation and respiratory responsive-
ness were not associated after AP exposure. These results 
suggest that the presence of abnormal airway smooth 
muscle function is determinant for respiratory respon-
siveness to LMW agents in this OA model, while the 
presence of mucosal airway inflammation may aggra-
vate the situation but is not the cause. Swedin et al. [25] 
also reported dissociation between airway inflammation 
and airway hyperresponsiveness (AHR) in an ovalbumin 
allergic mouse model, suggesting that inflammatory cells 
in BAL do not change in parallel with AHR. Regarding 
LMW agents, Vanoirbeek et  al. [22] observed the same 
pattern of dissociation in a mouse model of OA due to 
isocyanate. These results are consistent with previ-
ous observations in subjects with asthma in whom BAL 
inflammation was not a predictive surrogate marker of 
AHR [26], suggesting that other factors such as airway 
wall remodelling, the activation state of inflammatory 
cells, T-cell activation or autonomic dysfunction may 
play a more important role in the development of AHR. 
Recently, in a mouse model of severe asthma, Raundhal 
et al. [27] demonstrated a role for IFN-ϒ in the induction 
of AHR, whereas IL-17 promotes neutrophilic airway 
inflammation. These observations suggest that IFN-ϒ is 
the predominant cytokine associated with AHR in severe 
asthma and that airway inflammation and AHR may not 
always be linked.
The progressive reduction in responsiveness over time 
also occurs in patients with OA who cease exposure, 
although the results of the present study only partially 
reflect this situation. It is well established that patients 
with OA generally become less responsive to the sensi-
tizer after complete exposure removal [4]. Neverthe-
less, there is insufficient scientific evidence to assert that 
cessation of exposure improves asthma symptoms, and 
many patients do not become completely unresponsive 
to the sensitizer [28]. In our study, asthma symptoms and 
functional airway abnormalities had disappeared after 
90  days. However, our results did not prove that these 
mice would not become responsive if repeated exposures 
to the causal agent were given.
In conclusion, we show that both AHR and airway 
inflammation responses decrease with increasing time 
between sensitization and challenge. These findings sug-
gest that dermal contact with a chemical can cause long-
term sensitization and may lead to asthmatic symptoms. 
Moreover, many days after sensitization, exposure to the 
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causal agent may produce various responses of which 
AHR is the most persistent; for its part, the inflammation 
response may be decreased. In any case, the mechanisms 
underlying the process remain undefined and more stud-
ies in this direction are needed.
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